NDRA

+ Watchlist + Portfolio

ENDRA Life Sciences Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.52
52-Week Range: $2.96 – $9.85
Market Cap: $6.88M
P/E (TTM): —
EPS (TTM): -6.29
Dividend Yield: —

Advanced Metrics

Price/Book: 3.18
PEG Ratio: —
Return on Equity: -412.60%
Return on Assets: -122.33%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.64
Debt/Equity: 0.26
Total Debt: $461.21K
Free Cash Flow: $-5.42M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.78M

NDRA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.55M	$5.00M	$3.19M	$1.85M
Selling, General & Admin	$6.60M	$5.52M	$7.63M	$3.91M
Operating Expenses	$13.16M	$10.52M	$10.82M	$5.76M
Operating Income	-$13.16M	-$10.52M	-$10.82M	-$5.76M
EBITDA	-$12.92M	-$10.25M	-$10.61M	-$5.61M
Pretax Income	-$13.18M	-$10.06M	-$11.51M	-$7.03M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$13.18M	-$10.06M	-$11.51M	-$7.03M
Diluted EPS	-7980.00	-2766.85	-56.94	-8.93
Diluted Shares	1652	3636	202106	787020

NDRA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.89M	$2.83M	$3.23M	$762.37K
Inventory	$2.64M	—	—	—
Current Assets	$5.38M	$3.03M	$3.43M	$967.97K
Total Assets	$9.27M	$6.75M	$4.45M	$3.85M
Current Liabilities	$1.70M	$903.10K	$605.23K	$750.96K
Total Debt	$546.63K	$394.40K	$584.42K	$492.35K
Total Liabilities	$2.07M	$1.10M	$1.89M	$1.59M
Retained Earnings	-$81.87M	-$91.93M	-$103.44M	-$110.47M
Shareholders' Equity	$7.20M	$5.66M	$2.56M	$2.26M
Working Capital	$3.68M	$2.13M	$2.83M	$217.01K

NDRA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.77M	-$9.55M	-$7.40M	-$5.18M
Capital Expenditure	-$202.58K	-$33.88K	-$16.00K	-$3.02M
Free Cash Flow	-$12.97M	-$9.58M	-$7.42M	-$8.20M
Depreciation & Amortisation	$234.26K	$275.45K	$206.17K	$157.29K
Stock-Based Compensation	$1.20M	$996.43K	$571.92K	$329.41K
Investing Cash Flow	-$202.58K	-$24.72K	-$12.80K	-$3.02M
Financing Cash Flow	$8.40M	$7.52M	$7.81M	$5.73M
Net Change in Cash	-$4.57M	-$2.06M	$395.57K	-$2.47M

NDRA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$528.68K	$381.06K	$432.11K	$508.14K	$776.41K
Selling, General & Admin	$940.60K	$920.03K	$938.59K	$1.11M	$1.40M
Operating Expenses	$1.47M	$1.30M	$1.37M	$1.62M	$2.17M
Operating Income	-$1.47M	-$1.30M	-$1.37M	-$1.62M	-$2.17M
EBITDA	-$1.42M	-$1.27M	-$1.33M	-$1.58M	-$2.13M
Pretax Income	-$1.04M	-$1.23M	-$1.60M	-$3.17M	-$1.31M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$1.04M	-$1.23M	-$1.60M	-$3.17M	-$1.31M
Diluted EPS	-1.86	-1.71	-2.10	—	-1.09
Diluted Shares	557582	717107	761218	—	1.20M

NDRA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.06M	$1.81M	$794.04K	$762.37K	$356.46K
Current Assets	$2.18M	$1.85M	$1.05M	$967.97K	$536.67K
Total Assets	$3.17M	$2.81M	$1.96M	$3.85M	$3.44M
Current Liabilities	$565.78K	$576.64K	$800.31K	$750.96K	$835.44K
Total Debt	$587.30K	$557.49K	$525.33K	$492.35K	$461.21K
Total Liabilities	$1.42M	$1.33M	$1.79M	$1.59M	$1.65M
Retained Earnings	-$104.47M	-$105.70M	-$107.30M	-$110.47M	-$111.78M
Shareholders' Equity	$1.75M	$1.47M	$171.38K	$2.26M	$1.79M
Working Capital	$1.61M	$1.28M	$248.40K	$217.01K	-$298.77K

NDRA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.29M	-$1.11M	-$1.16M	-$1.61M	-$1.12M
Capital Expenditure	-$17.28K	—	—	-$3.00M	—
Free Cash Flow	-$1.31M	-$1.11M	-$1.16M	-$4.61M	-$1.12M
Depreciation & Amortisation	$45.58K	$32.79K	$39.39K	$39.53K	$39.72K
Stock-Based Compensation	$83.05K	$88.76K	$144.72K	$12.88K	$574.45K
Investing Cash Flow	-$17.28K	$0.00	$0.00	-$3.00M	$450.00K
Financing Cash Flow	$145.80K	$857.41K	$149.47K	$4.58M	$263.75K
Net Change in Cash	-$1.16M	-$256.30K	-$1.01M	-$31.67K	-$405.90K

Market Snapshot

About

ENDRA Life Sciences Inc. develops medical imaging technology focused on TAEUS (Thermo-Acoustic Enhanced UltraSound), a thermoacoustic imaging approach for visualizing tissue composition. The company targets liver disease detection and other diagnostic applications.